Surgery for VS reduces patients' QOL, and the preservation of hearing, achieved by using a middle fossa surgical approach, does not significantly alter this result.
Does EMSS Lead to Hearing Loss?

Analysis of Hearing Preservation After Endolymphatic Mastoid Sac Surgery for Meniere's Disease.
Sun GH, Leung R, et al: Laryngoscope 2010; 120 (March): 591-597 Although performing EMSS to treat the vertigo of Meniere's disease does not appear to be associated with an increased risk of deteriorating auditory function after treatment, surgery also does not confer an increased likelihood of stabilizing or improving hearing.
Background:
Meniere's disease (MD) is characterized by a combination of symptoms that classically include buzzing tinnitus, fluctuating low frequency unilateral hearing loss, aural fullness, and episodic vertigo. A popular surgical treatment has been endolymphatic mastoid sac surgery (EMSS) . Objective: To analyze hearing results after EMSS and medical therapy alone. Design: Retrospective review. Participants: 29 patients with definite MD were treated with EMSS and 29 patients were treated medically alone. Methods: Patients given an MD diagnosis between 1997 and 2006 were reviewed. Exclusion criteria included bilateral disease, prior ear surgery, conductive hearing loss, or transtympanic gentamicin treatment. Hearing was measured objectively using pure tone averages of 500, 1000, 2000, and 4000 Hertz as well as word recognition scores. Interventions: Medical therapy included low sodium diet and diuretic, and vestibular suppressants. Half the patients went on to EMSS. Results: The medical and EMSS groups were similar in terms of age, gender, and affected ear. The mean pretreatment pure tone average was statistically different in these 2 groups, as the medical management group tended to have better hearing at 34 dB as compared with 49 dB in the EMSS group. Average word recognition score was a little over 80% in both groups and did not change significantly during the study period. The average change in hearing was similar in the 2 groups. Hearing on average got 1 dB worse in the medically treated group and 4 dB better in the endolymphatic shunt group, but this was not a significant difference. Six patients had worse hearing after endolymphatic shunt surgery, and 3 patients developed worse hearing with medical therapy. Conclusions: EMSS did not cause hearing loss in this study. Reviewer's Comments: There have been other studies on hearing after EMSS, including a large series by Huang et al in 1991, which included 861 shunt surgeries with 12-year follow-up. This study also concluded that hearing tends to remain stable after EMSS. There have been a few reports of hearing improvement with EMSS, including some of the cases presented here. Although this study finds no significant change in hearing with endolymphatic shunt surgery, it also has a small sample size with only 29 patients undergoing the procedure. Others have reported a small risk of profound hearing loss with EMSS, which is probably around 1%, so a larger group of patients would be helpful in stratifying this risk. I would have liked to know what the success rate of controlling vertigo was in these patients, and if this was correlated with the hearing results. (Reviewer-Benjamin T. Crane, MD).
Long-Term Use of PPIs Can Increase Risk for Several Complications
Adverse Effects of Long-Term Proton Pump Inhibitor Use: A Review for the Otolaryngologist.
Chapman DB, Rees CJ, et al: J Voice 2010; February 6 (): epub ahead of print Doctors prescribing PPI therapy for LPR should consider obtaining DEXA bone mineral density scans, vitamin B 12 levels, and iron levels in at-risk patients.
Objective: To review pertinent literature related to potential side effects of proton pump inhibitor (PPI) therapy. Design: Literature review. Methods: A PubMed search was completed with key words PPI and adverse outcomes. Identified articles were compiled, reviewed, and discussed. Results: The majority of studies identified were epidemiological; therefore, a direct causative link between PPIs and adverse events was not possible in most cases. A number of adverse events were associated with long-term PPI use including reduced calcium absorption, Clostridium difficile-associated diarrhea, communityacquired pneumonia, cardiac events if combined with clopidogrel, and atrophic gastritis. Conclusions: Doctors prescribing PPI therapy for laryngopharyngeal reflux (LPR) should consider obtaining DEXA bone mineral density scans, vitamin B 12 levels, and iron levels in at-risk patients. Additionally, the authors recommend caution in the use of omeprazole in patients undergoing active treatment for acute coronary syndrome. Finally, in patients at risk for gastric carcinoma, testing for Helicobacter pylori or serum gastrin level may be appropriate. Reviewer's Comments: In 1988, Koufman et al estimated that 10% of individuals presenting to an otolaryngologist have complaints associated with reflux. These complaints may include dysphonia, dysphagia, globus, sore throat, post-nasal drip, chronic cough, and other upper airway symptoms. As PPIs have been established as the primary effective treatment for LPR, they are commonly utilized for management of these complaints. Although some potential side effects are well-known, previous to this report, there has been little attention given in the otolaryngology literature regarding potential adverse reactions to these medications. This report gives a concise, yet thorough review of potential adverse effects that the otolaryngologist should be aware of. Greater awareness of the role in gastroesophageal reflux disease (GERD) and LPR in otolaryngologic manifestations has led to an increased reliance on PPI therapy in the otolaryngology office. A 6-month minimum treatment period has been recommended for patients with LPR by the American Academy of Otolaryngology -Head and Neck Surgery. With such recommendations comes responsibility to consider potential acute or long-term side effects. The most common short-term side effects include nausea and/or vomiting, diarrhea, dizziness, and headache. Long-term effects may be of much greater concern given the potential to increase risk of bone fracture, pulmonary complications, cardiac events, or carcinoma. A number of articles (approximately 30) were reviewed by the authors and discussed in this series. As the authors acknowledge, most of the reports were epidemiological and therefore causation was not established. As a result, definitive change in care patterns may not be called for, but certainly awareness of potential issues should be taken into consideration clinically. Additionally, further research is warranted to better characterize these relationships for more accurate and concise risk analysis. (Reviewer-Heather Starmer, MA, CCC-SLP).
